Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression

Circulation

Volumn 115, Issue 14, 2007, Pages 1851-1857

  Berry, Colin ^a   L'Allier, Philippe L ^a   Grégoire, Jean ^a   Lespérance, Jacques ^a   Levesque, Sylvie ^a   Ibrahim, Reda ^a   Tardif, Jean Claude ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Angiography; Atherosclerosis; Coronary disease; Ultrasonics

Indexed keywords

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROMA; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; HUMAN; INTERMETHOD COMPARISON; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 34247165400     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.655654     Document Type: Article

References (29)

1. The Principal Investigators of CASS and Their Associates. The National Heart, Lung, and Blood Institute Coronary Artery Surgery Study. Circulation. 1981;63(suppl II):II1-II39.
2. Cashinhemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA. 1990;264:3013-3017.
3. Waters D, Lesperance J. Regression of coronary atherosclerosis: an achievable goal? Review of results from recent clinical trials. Am J Med. 1991;91:S10-S17.
4. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lesperance J. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994;89:959-968.
5. Brown BG, Zhao XQ, Chait A, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
6. Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, Sparler S, Armstrong WT, Ports TA, Kirkeeide RL, Hogeboom C, Brand RJ. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998;280:2001-2007.
7. Roberts WC, Jones AA. Quantitation of coronary arterial narrowing at necropsy in sudden coronary death. Am J Cardiol. 1971;44:39-44.
8. Isner JM, Kishel J, Kent KM. Accuracy of angiographic determination of left main coronary arterial narrowing. Circulation. 1981;63:1056-1061.
9. White CW, Wright CB, Doty DB, Hiratza LF, Eastham CL, Harrison DG, Marcus ML. Does visual interpretation of the coronary angiogram predict the physiologic importance of a coronary stenosis? N Engl J Med. 1984;310:819-824.
10. Grondin CM, Dyrda I, Pasternac A, Campeau L, Bourassa MG. Discrepancies between cine-angiographic and post-mortem findings in patients with coronary artery disease and recent myocardial revascularization. Circulation. 1974;49:703-756.
11. De Scheerder I, De Man F, Herregods MC, Wilczek K, Barrios L, Raymenants E, Desmet W, De Geest H, Piessens J. Intravascular ultrasound versus angiography for measurement of luminal diameters in normal and diseased coronary-arteries. Am Heart J. 1994;127:243-251.
12. Ito K, Yamagishi M, Yasumura Y, Nakatani S, Yasuda S, Miyatake K. Impact of coronary artery remodeling on misinterpretation of angiographic disease eccentricity: evidence from intravascular ultrasound. Int J Cardiol. 1999;70:275-282.
13. Guedes A, Tardif JC. Intravascular ultrasound assessment of atherosclerosis. Curr Atheroscler Rep. 2004;6:219-224.
14. Nissen SE, Gurley JC, Grines CL, Booth DC, McClure R, Berk M, Fischer C, DeMaria AN. Intravascular ultrasound assessment of lumen size and wall morphology in normal subjects and patients with coronary-artery disease. Circulation. 1991;84:1087-1099.
15. Takazawa K, Fujita M, Tanaka N, Takeda K, Ishimaru M, Kowaguchi H, Matsuoka O, Kurosu F, Tamura S, Ibukiyama C. Comparison of lumen area after PTCA by IVUS and QCA. Heart Vessels. 1997;suppl 12:217-220.
16. Yamagishi M, Hosokawa H, Saito S, Kanemitsu S, Chino M, Koyanagi S, Urasawa K, Honye J, Nakamura M, Matsumoto T, Kitabatake A, Takekoshi N, Yamaguchi T. Coronary disease morphology and distribution determined by quantitative angiography and intravascular ultrasound: re-evaluation in a Cooperative Multicenter Intravascular Ultrasound Study (COMIUS). Circ J. 2002;66:735-740.
17. Varnava AM, Davies MJ. Relation between coronary artery remodelling (compensatory dilatation) and stenosis in human native coronary arteries. Heart. 2001;86:207-211.
18. Schoenagen P, Ziada KM, Kapadia SR, Crowe TD, Nissen SE, Tuzcu EM. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation. 2000;101:598-603.
19. Guedes A, Keller PF, L'Allier PL, Lesperance J, Gregoire J, Tardif JC. Long-term safety of intravascular ultrasound in nontransplant, nonintervened, atherosclerotic coronary arteries. J Am Coll Cardiol. 2005;45:559-564.
20. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300.
21. Tardif JC, Gregoire J, L'Allier PL, Anderson TJ, Bertrand O, Reeves F, Title LM, Alfonso F, Schampaert E, Hassan A, McLain R, Pressier ML, Ibrahim R, Lesperance J, Blue J, Heinonen T, Rodes-Cabau J; Avasimibe and Progression of Lesions on UltraSound (A-PLUS) Investigators. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human coronary atherosclerotic lesions. Circulation. 2004;110:3372-3377.
22. Tardif JC, Heinonen T, Orloff D, Libby P. Vascular biomarkers and surrogates in cardiovascular disease. Circulation. 2006;113:2936-2942.
23. Tardif JC, Gregoire J, Lesperance J, Lambert J, L'Allier PL, Rodes J, Anderson T, Blue JW, Imus J, Heinonen T. Design features of the Avasimibe and Progression of Coronary Lesions Assessed by Intravascular UltraSound (A-PLUS) clinical trial. Am Heart J. 2002;144:589-596.
24. Waters D, Lesperance J, Craven TE, Hudon G, Gillam LD. Advantages and limitations of serial coronary arteriography for the assessment of progression and regression of coronary atherosclerosis: implications for clinical trials. Circulation. 1993;87(suppl II):38-47.
25. Waters D, Lesperance J, Francetich M, Causey D, Theroux P, Chiang YK, Hudon G, Lemarbre L, Reitman M, Joyal M. A controlled clinical trial to assess the effect of a calcium-channel blocker on the progression of coronary atherosclerosis. Circulation. 1990;82:1940-1953.
26. Solymoss BC, Bourassa MG, Campeau L, Sniderman A, Marcil M, Lesperance J, Levesque S, Varga S. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol. 2004;93:159-164.
27. Reiber JHC. Advances in Quantitative Coronary Arteriography. Dordrecht, Netherlands: Kulwer Academic Publishers; 1993:387.
28. Tardif JC, Bertrand OF, Mongrain R, Lesperance J, Gregoire J, Paiement P, Bonan R. Reliability of mechanical and phased-array designs for serial intravascular ultrasound examinations: animal and clinical studies in stented and non-stented coronary arteries. Intern J Card Imaging. 2000;16:365-375.
29. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lavoie MA, LeMay M, Cohen E, Keller PF, Heinonen T, Guertin MC. Effect of atherosclerotic regression on total luminal size of coronary arteries as determined by intravascular ultrasound. Am J Cardiol. 2006;98:23-27.